Evidence map›Paper›PMID 23136849›Full record

ArticleACS nano2012

Designing biomaterials to direct stem cell fate.

Chaenyung Cha, William B Liechty, Ali Khademhosseini, Nicholas A Peppas

Abstract read
In one paragraph

Article in ACS nano, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chaenyung ChaCenter for Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, United States.
William B Liechty
Ali Khademhosseini
Nicholas A Peppas

Funding

pH Sensitive Complex Hydrogels for Protein Drug ReleaseR01EB000246 · NIBIB · UNIVERSITY OF TEXAS AUSTIN · PI LOWMAN, ANTHONY M, PEPPAS, NICHOLAS A · 2002 to 2014
$3.8M
Microfabricated Vascularized 3D Tissue Engineered ConstructsR01HL092836 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI · 2008 to 2012
$2.4M
Thermally Responsive Magnetic-Hydrogel Nanocomposites for Advanced Drug DeliveryR21EB012726 · NIBIB · UNIVERSITY OF TEXAS AT AUSTIN · PI PEPPAS, NICHOLAS A · 2011 to 2012
$393k
NHLBI NIH HHS HL-092836-05NHLBI NIH HHS R01 HL092836NIBIB NIH HHS EB-000246-18NIBIB NIH HHS EB-012726-02NIBIB NIH HHS R01 EB000246NIBIB NIH HHS R21 EB012726
6 · The paper itself

Abstract

As stem cells are a cornerstone of regenerative medicine, research efforts have been extensively focused on controlling their self-renewal and differentiation. It is well-known that stem cells are tightly regulated by a combination of physical and chemical factors from their complex extracellular surroundings; thus, conventional cell culture approaches based purely on using soluble factors to direct stem cell fate have resulted in limited success. To account for the complexities of native stem-cell niches, biomaterials are actively investigated as artificial extracellular matrices in order to mimic the natural microenvironment. This Perspective highlights important areas related to the design of biomaterials to control stem cell behavior, such as cell-responsive ligands, mechanical signals, and delivery of soluble factors.

Indexed as

AnimalsBiocompatible MaterialsBiomimetic MaterialsCell DifferentiationCell ProliferationCells, CulturedCell SurvivalHumansNanoparticlesStem CellsBiocompatible Materials

Identifiers

PMID23136849
PMCPMC3508394

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.